One of the remedies available to intellectual property owners introduced by what is known as the Enforcement Directive was the publication of the judgment where infringement is declared. This remedy was already foreseen in article 63 of the 1986 Spanish Patents Act, which includes among the remedies available to the patent owner, inter alia, “the…
On 3 September 2012, the Adminstrative Court decision in the Italian antitrust case involving Pfizer was published. This decision completely reversed the ruling of the Italian Antitrust Authority which had initially found Pfizer guilty of abuse of dominant position and applied a 10.6 million euro fine (see my earlier post here). In substance, the Administrative…
In countries where patents and utility models (sometimes called “petty patents”) co-exist, a recurrent question is which is the level of inventiveness required for utility models as opposed to patents. According to article 8 of Spain’s 1986 Patents Act, which mirrors article 56 of the European Patent Convention, an invention protected by a patent is…
Applying a purposive construction of the claims the Court found no infringement similar to the conclusion in prior parallel proceedings between the parties in the Netherlands, Germany and the United Kingdom. The issue of added matter was left to be addressed in a separate judgment. Click here for the full text of this case. A summary…
The Court cited the parallel proceedings between the parties in the United Kingdom, where the approach of the EPO Board of Appeal in T331/87 Houdaille/Removal of Feature [1991] EPOR 194 was applied, and concluded that the changes in the patent amount to added matter. Click here for the full text of this case. A summary of…
The Court of Appeal held that Roche c.s. infringed the patent. Test results regarding the allegedly infringing product were admitted as evidence because Roche’s arguments were held insufficient to render these tests unreliable. Furthermore, the court ruled that it has jurisdiction to decide on the infringement in Germany based on Art. 24 EC 44/2001, because…
The Court of Appeal partially reversed the Brussels Commercial Court’s decision invalidating Lundbeck’s SPC for escitalopram, to the extent that it had immediate effect. A summary of this case will be posted on http://www.KluwerIPCases.com
The Brussels Court of Appeal issued a preliminary injunction against Eurogenerics on the basis of Lundbeck’s Belgian SPC for escitalopram, despite the fact that the SPC had been invalidated in earlier proceedings, the court found that, given the suspensive effect of the appeal against the decision invalidating the SPC, a preliminary injunction could be granted…
On 27 September 2012, a new consolidated version of the Draft Agreement on a Unified Patent Court (Document 14268/12) was (finally) published. The consolidated text includes some of the amendments agreed upon on 5 December 2011 as well as on the 29/30 June 2012 EU Council summit, and also presents further amendments and quite a…
In the wake of the UPC Agreement having been entered into under the Danish presidency, there was widespread euphoria about the many, potentially positive, aspects of Danish SME litigants being able to save substantial costs under the envisaged UPC regime. The Danish press abounded in positive reviews put forward by politicians and industry representatives alike,…
